Merck KGaA's Cladribine Revival Smacks Of Desperation
This article was originally published in Scrip
Executive Summary
In a surprise development, Merck KGaA has decided to file for approval of cladribine, the oral multiple sclerosis medicine it suspended in late-stage trials more than four years ago. It now says that, having evaluated new data and done additional analyses of the product's benefit-risk profile, it will file for approval in Europe in the first half of 2016, and that it is developing plans for filings in other markets.
You may also be interested in...
Merck KGaA Foresees Mid-2019 US Launch Of Oral MS Therapy Mavenclad
German Merck tells Scrip Mavenclad's long spell in the regulatory 'wilderness' allowed it to amass deep safety and efficacy data that should help the oral MS drug's commercial prospects.
Interview: German Merck Set For Big "Leap" In India
Germany's Merck Group appears set to build on its strong showing in India. Belén Garijo, CEO of Healthcare at Merck KGAA, tells Scrip about efforts to "consumerize" the firm's primary care business, how Erbitux is the "backbone" on which the company will build its oncology presence, and plans to roll out new products including the clinical stage immune-oncology asset avelumab, in India.
Merck KGaA Previews Cladribine Regulatory Revival Story At ECTRIMS
With the EMA’s review of the latest MAA for cladribine ongoing, Merck KGaA uses ECTRIMS 2016 to showcase longer-term efficacy data and a safety analysis that could lay to rest concerns about the multiple sclerosis therapy's risk of malignancy.